Age: 27.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Paraesthesia oral, Pharyngeal paraesthesia, Pregnancy test urine, Tachycardia, Throat irritation
Clinical narrative: burning, tingling sensation started in the chest and rapidly intensified, moving into throat, mouth, tongue, nose, and ears; burning, tingling sensation started in the chest and rapidly intensified, moving into throat, mouth, tongue, nose, and ears; burning, tingling sensation started in the chest and rapidly intensified, moving into throat, mouth, tongue, nose, and ears; burning, tingling sensation started in the chest and rapidly intensified, moving into throat, mouth, tongue, nose, and ears; burning, tingling sensation started in the chest and rapidly intensified, moving into throat, mouth, tongue, nose, and ears; burning, tingling sensation started in the chest and rapidly intensified, moving into throat, mouth, tongue, nose, and ears; burning, tingling sensation started in the chest and rapidly intensified, moving into throat, mouth, tongue, nose, and ears; burning, tingling sensation started in the chest and rapidly intensified, moving into throat, mouth, tongue, nose, and ears; burning, tingling sensation started in the chest and rapidly intensified, moving into throat, mouth, tongue, nose, and ears; burning, tingling sensation started in the chest and rapidly intensified, moving into throat, mouth, tongue, nose, and ears; elevated heart rate; This is a spontaneous report from a contactable nurse.  A 27-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; Lot number: EL0140), via an unspecified route of administration, on 22Dec2020 12:00 (at the age of 27-years-old) at a single dose for COVID-19 immunization. Medical history included Hashimoto's hypothyroidism, anxiety, and 5 months postpartum and breastfeeding. The patient was not pregnant at the time of vaccination. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications, taken within two weeks of vaccination, included levothyroxine (MANUFACTURER UNKNOWN), sertraline hydrochloride (ZOLOFT), ascorbic acid, calcium pantothenate, cyanocobalamin, ergocalciferol, nicotinamide, pyridoxine hydrochloride, retinol palmitate, riboflavin, thiamine mononitrate (PRENATAL VITAMINS; MANUFACTURER UNKNOWN). Other concomitant medications included unspecified cough drops. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced a burning, tingling sensation started in the chest and rapidly intensified, moving into throat, mouth, tongue, nose, and ears on 22Dec2020 12:15 and elevated heart rate on 22Dec2020. It was reported that the events mostly resolved within a few minutes and the patient took off her mask, sat down and drank water. The patient was evaluated in the emergency room and released after a couple of hours. The patient underwent lab tests and procedures which included electrocardiogram (EKG): normal on 22Dec2020 and heart rate: elevated on 22Dec2020; no labs were conducted in the emergency room. The clinical outcome of all the events was recovered in Dec2020. It was also reported that since the vaccination, the patient had not been tested for COVID-19.  The batch/lot number for the vaccine, BNT162B2, was not provided and has been requested during follow up.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2020511679 mother case